Form 4: Sanara MedTech Director Receives Stock Grant

Director Roszell Mack III was granted 5,308 shares of restricted common stock in Sanara MedTech Inc.

Summary

• Director Roszell Mack III acquired 5,308 shares of common stock in Sanara MedTech Inc. (SMTI).
• The shares were granted as restricted stock under the 2024 Omnibus Long-Term Incentive Plan.
• The grant price is listed as $0, indicating an equity compensation award.
• Following this transaction, the director's total beneficial ownership is 21,842 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Retention of key leadership through a one-year vesting schedule.

Negatives

• Dilutive effect of new share issuance on existing shareholders.

Risks

• Vesting is contingent upon the director continuing to provide services to the issuer through the vesting date.

Future Outlook

The restricted stock is scheduled to vest on the earlier of the 2027 annual shareholder meeting or June 4, 2027, subject to continued service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices designed to align board incentives with long-term shareholder value in the medical technology sector.

Comparison to Industry Standards

• The use of an Omnibus Long-Term Incentive Plan is consistent with standard compensation practices for small-cap medical device companies.
• Vesting periods of one year for director equity grants are common practice among peers in the healthcare sector.

Stakeholder Impact

• Shareholders experience minor dilution from the issuance of new restricted shares.

Next Steps

• Vesting of the 5,308 shares on or before June 4, 2027.

Key Dates

Keywords

Sanara MedTech, SMTI, Form 4, Insider Trading, Equity Compensation, Director Compensation